Maedi Visna Virus (MVV) causes a chronic viral disease in sheep. Since there is no specific therapeutic drug that targets MVV, development of a vaccine against the MVV is inevitable. This study aimed to analyze the gag and env proteins as vaccine candidate proteins and to identify epitopes in these proteins. In addition, it was aimed to construct a multi-epitope vaccine candidate. According to the obtained results, the gag protein was detected to be more conserved and had a higher antigenicity value. Also, the number of alpha helix in the secondary structure was higher and transmembrane helices were not detected. Although many B cell and MHC-I/II epitopes were predicted, only 19 of them were detected to have the properties of antigenic, non-allergenic, non-toxic, soluble, and non-hemolytic. Of these epitopes, five were remarkable due to having the highest antigenicity value. However, the final multi-epitope vaccine was constructed with 19 epitopes. A strong affinity was shown between the final multi-epitope vaccine and TLR-2/4. In conclusion, the gag protein was a better antigen. However, both proteins had epitopes with high antigenicity value. Also, the final multi-epitope vaccine construct had a potential to be used as a peptide vaccine due to its immuno-informatics results.

梅迪维斯纳病毒 (MVV) 会引起绵羊的慢性病毒性疾病。由于尚无针对 MVV 的特异性治疗药物，因此开发针对 MVV 的疫苗是不可避免的。本研究旨在分析作为疫苗候选蛋白的 gag 和 env 蛋白，并鉴定这些蛋白中的表位。此外，其目的还在于构建一种多表位候选疫苗。根据所得结果，检测gag蛋白较为保守，具有较高的抗原性值。此外，二级结构中的α螺旋数量较多，并且未检测到跨膜螺旋。尽管预测了许多B细胞和MHC-I/II表位，但只有19个被检测到具有抗原性、非过敏性、无毒性、可溶性和非溶血性。在这些表位中，有五个由于具有最高的抗原性值而引人注目。然而，最终的多表位疫苗是由 19 个表位构建的。最终的多表位疫苗与TLR-2/4之间显示出很强的亲和力。总之，gag 蛋白是更好的抗原。然而，这两种蛋白质都具有高抗原性值的表位。此外，由于其免疫信息学结果，最终的多表位疫苗构建体有可能用作肽疫苗。